The utility of insulin glargine in the treatment of diabetes mellitus

Jeffrey Stroup, Michael P. Kane, Robert S. Busch, Gary Bakst, Robert A. Hamilton

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Study Objectives. To compare hemoglobin A1c (A1C) values at baseline with those after 1 year of insulin glargine therapy and, secondarily, to compare insulin dosage and patients' body weight at baseline and at 1 year. Design. Retrospective study. Setting. Private endocrinology practice. Patients. One hundred ninety-seven patients with diabetes mellitus who were first prescribed insulin glargine from May 2001-April 2002 and were evaluable after 1 year of therapy. Intervention. Patients received insulin glargine instead of NPH insulin or in addition to their oral drug therapy. Measurements and Main Results. Patients with diabetes type 1 (receiving insulin therapy) or type 2 (receiving oral drug therapy only, a combination of oral drug therapy and insulin, or insulin only) who had been treated with insulin glargine for 1 year were evaluated. Overall, A1C values decreased significantly (p<0.001) by 0. 53 ± 1.4% from a baseline mean of 8.1 ± 1.7%. In 129 patients with type 2 diabetes previously treated with NPH insulin, A1C decreased significantly (p<0.001) 0.57 ± 1.5% from baseline. The A1C decreased by 0.71 ± 1.3% (p=0.0043) from baseline in 33 patients with type 2 diabetes who previously received oral agents only. Thirty-five patients with type 1 diabetes demonstrated no significant change in A1C (-0.22 ± 1.0%, p=0.217) from baseline. In patients receiving insulin at baseline, the number of daily injections increased significantly (p<0.0001) from a median of two at baseline to three at 1 year. Overall, no significant change was noted in total daily insulin requirement or in body weight in any of the patient groups over the 1-year period. Conclusion. Compared with baseline, insulin glargine therapy at 1 year was associated with an overall significant reduction in A1C of 0.53 ± 1.4%.

Original languageEnglish
Pages (from-to)736-742
Number of pages7
JournalPharmacotherapy
Volume24
Issue number6
DOIs
StatePublished - 1 Jun 2004

Fingerprint

Diabetes Mellitus
Insulin
Isophane Insulin
Therapeutics
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Body Weight
Insulin Glargine
Drug Therapy
Endocrinology
Private Practice
Combination Drug Therapy
Hemoglobins
Retrospective Studies
Injections

Keywords

  • Diabetes mellitus
  • Glycemic control
  • Hemoglobin A
  • Hyperglycemia
  • Hypoglycemia
  • Insulin glargine
  • NPH insulin

Cite this

Stroup, Jeffrey ; Kane, Michael P. ; Busch, Robert S. ; Bakst, Gary ; Hamilton, Robert A. / The utility of insulin glargine in the treatment of diabetes mellitus. In: Pharmacotherapy. 2004 ; Vol. 24, No. 6. pp. 736-742.
@article{848f18f9223344e78d146636363a28c8,
title = "The utility of insulin glargine in the treatment of diabetes mellitus",
abstract = "Study Objectives. To compare hemoglobin A1c (A1C) values at baseline with those after 1 year of insulin glargine therapy and, secondarily, to compare insulin dosage and patients' body weight at baseline and at 1 year. Design. Retrospective study. Setting. Private endocrinology practice. Patients. One hundred ninety-seven patients with diabetes mellitus who were first prescribed insulin glargine from May 2001-April 2002 and were evaluable after 1 year of therapy. Intervention. Patients received insulin glargine instead of NPH insulin or in addition to their oral drug therapy. Measurements and Main Results. Patients with diabetes type 1 (receiving insulin therapy) or type 2 (receiving oral drug therapy only, a combination of oral drug therapy and insulin, or insulin only) who had been treated with insulin glargine for 1 year were evaluated. Overall, A1C values decreased significantly (p<0.001) by 0. 53 ± 1.4{\%} from a baseline mean of 8.1 ± 1.7{\%}. In 129 patients with type 2 diabetes previously treated with NPH insulin, A1C decreased significantly (p<0.001) 0.57 ± 1.5{\%} from baseline. The A1C decreased by 0.71 ± 1.3{\%} (p=0.0043) from baseline in 33 patients with type 2 diabetes who previously received oral agents only. Thirty-five patients with type 1 diabetes demonstrated no significant change in A1C (-0.22 ± 1.0{\%}, p=0.217) from baseline. In patients receiving insulin at baseline, the number of daily injections increased significantly (p<0.0001) from a median of two at baseline to three at 1 year. Overall, no significant change was noted in total daily insulin requirement or in body weight in any of the patient groups over the 1-year period. Conclusion. Compared with baseline, insulin glargine therapy at 1 year was associated with an overall significant reduction in A1C of 0.53 ± 1.4{\%}.",
keywords = "Diabetes mellitus, Glycemic control, Hemoglobin A, Hyperglycemia, Hypoglycemia, Insulin glargine, NPH insulin",
author = "Jeffrey Stroup and Kane, {Michael P.} and Busch, {Robert S.} and Gary Bakst and Hamilton, {Robert A.}",
year = "2004",
month = "6",
day = "1",
doi = "10.1592/phco.24.8.736.36064",
language = "English",
volume = "24",
pages = "736--742",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Wiley-Blackwell",
number = "6",

}

The utility of insulin glargine in the treatment of diabetes mellitus. / Stroup, Jeffrey; Kane, Michael P.; Busch, Robert S.; Bakst, Gary; Hamilton, Robert A.

In: Pharmacotherapy, Vol. 24, No. 6, 01.06.2004, p. 736-742.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The utility of insulin glargine in the treatment of diabetes mellitus

AU - Stroup, Jeffrey

AU - Kane, Michael P.

AU - Busch, Robert S.

AU - Bakst, Gary

AU - Hamilton, Robert A.

PY - 2004/6/1

Y1 - 2004/6/1

N2 - Study Objectives. To compare hemoglobin A1c (A1C) values at baseline with those after 1 year of insulin glargine therapy and, secondarily, to compare insulin dosage and patients' body weight at baseline and at 1 year. Design. Retrospective study. Setting. Private endocrinology practice. Patients. One hundred ninety-seven patients with diabetes mellitus who were first prescribed insulin glargine from May 2001-April 2002 and were evaluable after 1 year of therapy. Intervention. Patients received insulin glargine instead of NPH insulin or in addition to their oral drug therapy. Measurements and Main Results. Patients with diabetes type 1 (receiving insulin therapy) or type 2 (receiving oral drug therapy only, a combination of oral drug therapy and insulin, or insulin only) who had been treated with insulin glargine for 1 year were evaluated. Overall, A1C values decreased significantly (p<0.001) by 0. 53 ± 1.4% from a baseline mean of 8.1 ± 1.7%. In 129 patients with type 2 diabetes previously treated with NPH insulin, A1C decreased significantly (p<0.001) 0.57 ± 1.5% from baseline. The A1C decreased by 0.71 ± 1.3% (p=0.0043) from baseline in 33 patients with type 2 diabetes who previously received oral agents only. Thirty-five patients with type 1 diabetes demonstrated no significant change in A1C (-0.22 ± 1.0%, p=0.217) from baseline. In patients receiving insulin at baseline, the number of daily injections increased significantly (p<0.0001) from a median of two at baseline to three at 1 year. Overall, no significant change was noted in total daily insulin requirement or in body weight in any of the patient groups over the 1-year period. Conclusion. Compared with baseline, insulin glargine therapy at 1 year was associated with an overall significant reduction in A1C of 0.53 ± 1.4%.

AB - Study Objectives. To compare hemoglobin A1c (A1C) values at baseline with those after 1 year of insulin glargine therapy and, secondarily, to compare insulin dosage and patients' body weight at baseline and at 1 year. Design. Retrospective study. Setting. Private endocrinology practice. Patients. One hundred ninety-seven patients with diabetes mellitus who were first prescribed insulin glargine from May 2001-April 2002 and were evaluable after 1 year of therapy. Intervention. Patients received insulin glargine instead of NPH insulin or in addition to their oral drug therapy. Measurements and Main Results. Patients with diabetes type 1 (receiving insulin therapy) or type 2 (receiving oral drug therapy only, a combination of oral drug therapy and insulin, or insulin only) who had been treated with insulin glargine for 1 year were evaluated. Overall, A1C values decreased significantly (p<0.001) by 0. 53 ± 1.4% from a baseline mean of 8.1 ± 1.7%. In 129 patients with type 2 diabetes previously treated with NPH insulin, A1C decreased significantly (p<0.001) 0.57 ± 1.5% from baseline. The A1C decreased by 0.71 ± 1.3% (p=0.0043) from baseline in 33 patients with type 2 diabetes who previously received oral agents only. Thirty-five patients with type 1 diabetes demonstrated no significant change in A1C (-0.22 ± 1.0%, p=0.217) from baseline. In patients receiving insulin at baseline, the number of daily injections increased significantly (p<0.0001) from a median of two at baseline to three at 1 year. Overall, no significant change was noted in total daily insulin requirement or in body weight in any of the patient groups over the 1-year period. Conclusion. Compared with baseline, insulin glargine therapy at 1 year was associated with an overall significant reduction in A1C of 0.53 ± 1.4%.

KW - Diabetes mellitus

KW - Glycemic control

KW - Hemoglobin A

KW - Hyperglycemia

KW - Hypoglycemia

KW - Insulin glargine

KW - NPH insulin

UR - http://www.scopus.com/inward/record.url?scp=2942616447&partnerID=8YFLogxK

U2 - 10.1592/phco.24.8.736.36064

DO - 10.1592/phco.24.8.736.36064

M3 - Article

C2 - 15222663

AN - SCOPUS:2942616447

VL - 24

SP - 736

EP - 742

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 6

ER -